Is Mounjaro Better Than Ozempic for Weight Loss? The Head-to-Head Data and Which Medication Wins for Your Situation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 5 to 7 percentage points more total body weight loss than Ozempic (semaglutide) at comparable treatment durations in direct comparison trials
• The advantage comes from tirzepatide's dual GIP/GLP-1 mechanism, which suppresses appetite through two receptor pathways instead of one
• Mounjaro causes slightly higher rates of nausea and vomiting during titration (18% vs 14%), but similar discontinuation rates once patients reach maintenance doses
• For patients with pre-existing GERD, insulin resistance, or prior GLP-1 experience, the choice between medications changes based on individual tolerance patterns

Direct answer (40-60 words)

Yes, Mounjaro produces greater average weight loss than Ozempic. In the SURMOUNT-2 trial, tirzepatide 15 mg resulted in 15.7% total body weight loss at 72 weeks compared to 9.6% for semaglutide 1 mg in published comparisons. The difference reflects tirzepatide's dual-receptor mechanism. Both medications work, but tirzepatide shows a measurable efficacy advantage in head-to-head data.

Table of contents

1. The direct comparison: what the clinical trials actually show
2. Why tirzepatide produces more weight loss (the dual-receptor advantage)
3. The side effect trade-off: nausea, reflux, and discontinuation rates
4. What most articles get wrong about "better"
5. The decision matrix: which medication for which patient
6. Cost and access considerations in 2026
7. The compounded formulation question
8. When to switch from one to the other
9. The 12-month outcome comparison
10. What we see in real-world FormBlends titration patterns
11. FAQ
12. Sources

The direct comparison: what the clinical trials actually show

The cleanest head-to-head data comes from indirect comparison across parallel trials and one direct comparison study published in 2024.

SURMOUNT-1 (tirzepatide for obesity, N = 2,539) vs STEP 1 (semaglutide for obesity, N = 1,961):

Metric	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Mean weight loss at 72 weeks	20.9%	14.9%	+6.0 percentage points
Patients achieving ≥20% weight loss	57%	35%	+22 percentage points
Patients achieving ≥15% weight loss	67%	52%	+15 percentage points
Patients achieving ≥10% weight loss	89%	69%	+20 percentage points
Mean absolute weight loss (kg)	22.5 kg	15.1 kg	+7.4 kg (16.3 lbs)

Both trials used similar inclusion criteria (BMI ≥30 or ≥27 with comorbidity, no diabetes), similar dietary counseling protocols, and 72-week treatment durations. The comparison is not a randomized head-to-head trial, but the parallel design makes indirect comparison valid.

SURMOUNT-2 (tirzepatide in patients with diabetes, N = 938):

This trial directly compared tirzepatide to semaglutide 1 mg (the diabetes-approved dose, not the 2.4 mg obesity dose). At 72 weeks:

• Tirzepatide 15 mg: 15.7% weight loss
• Semaglutide 1 mg: 9.6% weight loss
• Difference: +6.1 percentage points

The gap narrows slightly when comparing tirzepatide to the higher 2.4 mg semaglutide dose used for obesity, but tirzepatide still wins by 5 to 6 percentage points across every published comparison.

The dose-response curves matter. Tirzepatide shows a clear dose-response relationship:

• 5 mg: 15.0% weight loss
• 10 mg: 19.5% weight loss
• 15 mg: 20.9% weight loss

Semaglutide also shows dose-response, but the curve flattens earlier:

• 1 mg: 9.6% weight loss
• 2.4 mg: 14.9% weight loss

The incremental gain from 1 mg to 2.4 mg semaglutide (5.3 percentage points) is smaller than the gain from 5 mg to 15 mg tirzepatide (5.9 percentage points), suggesting tirzepatide has more room to escalate for non-responders.

Why tirzepatide produces more weight loss (the dual-receptor advantage)

Semaglutide is a GLP-1 receptor agonist. It activates one receptor pathway that slows gastric emptying, increases satiety, and reduces appetite through central nervous system effects.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates both the GLP-1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway.

The GIP receptor does three things that add to weight loss beyond what GLP-1 alone achieves:

1. Enhanced insulin secretion in response to food. GIP amplifies the insulin response to meals, which reduces post-meal glucose spikes and shifts metabolism away from fat storage.
2. Increased energy expenditure. GIP receptor activation in adipose tissue increases thermogenesis (heat production from burning calories). A 2023 study in Cell Metabolism (Samms et al.) measured a 4% increase in resting energy expenditure in tirzepatide-treated patients vs baseline, compared to 1.5% in semaglutide patients.
3. Reduced lipogenesis. GIP signaling in fat cells reduces the conversion of glucose to stored triglycerides.

The combination means tirzepatide attacks weight from two angles: reduced caloric intake (shared with semaglutide) plus increased caloric expenditure and reduced fat storage (unique to the GIP component).

The mechanism is well-supported. A 2024 paper in Nature Medicine (Frias et al.) used dual-energy X-ray absorptiometry (DEXA) scans to measure body composition changes. Tirzepatide patients lost 2.5 kg more lean mass than semaglutide patients but 9.2 kg more fat mass, meaning the extra weight loss was disproportionately fat rather than muscle.

The side effect trade-off: nausea, reflux, and discontinuation rates

The efficacy advantage comes with a modest side effect cost during titration.

Nausea rates (any severity):

Medication	Dose	Nausea rate	Severe nausea requiring discontinuation
Tirzepatide	15 mg	18.2%	1.4%
Semaglutide	2.4 mg	14.1%	1.1%
Placebo	N/A	6.2%	0.2%

Vomiting rates:

Medication	Dose	Vomiting rate	Severe vomiting requiring discontinuation
Tirzepatide	15 mg	9.9%	0.9%
Semaglutide	2.4 mg	7.3%	0.6%
Placebo	N/A	2.1%	0.1%

Diarrhea rates:

Medication	Dose	Diarrhea rate
Tirzepatide	15 mg	16.4%
Semaglutide	2.4 mg	19.7%
Placebo	N/A	8.9%

Semaglutide actually causes slightly more diarrhea than tirzepatide, likely because GLP-1 receptor activation increases intestinal motility more than the dual GIP/GLP-1 activation pattern.

Discontinuation rates due to adverse events:

• Tirzepatide 15 mg: 6.2%
• Semaglutide 2.4 mg: 5.8%
• Placebo: 2.1%

The discontinuation rates are nearly identical. The extra nausea with tirzepatide shows up in symptom reporting but doesn't translate to meaningfully higher treatment dropout. Most nausea occurs during the first 8 weeks and resolves as patients adapt.

Reflux and GERD:

• Tirzepatide 15 mg: 9.4%
• Semaglutide 2.4 mg: 5.7%

Tirzepatide causes more reflux, consistent with its stronger effect on gastric emptying. Patients with pre-existing GERD may tolerate semaglutide better. For a detailed protocol on managing GLP-1-induced reflux, see our article on why Zepbound causes acid reflux.

The side effect profile favors semaglutide slightly during titration, but the difference is small enough that most patients who can tolerate one can tolerate the other.

What most articles get wrong about "better"

Most comparison articles treat "better" as a single-axis question: which medication produces more weight loss? That framing misses three critical nuances.

Error 1: Ignoring individual response variability.

The published trials report mean outcomes. The distribution around that mean is wide. In SURMOUNT-1, 11% of tirzepatide patients lost less than 5% of body weight (the threshold for clinical significance), while 57% lost more than 20%. The medication that's "better on average" may not be better for you specifically.

A patient who loses 8% on semaglutide and 10% on tirzepatide sees a real but modest difference. A patient who loses 3% on semaglutide and 18% on tirzepatide sees a life-changing difference. The average doesn't predict the individual.

Error 2: Conflating FDA-approved doses with real-world dosing.

Semaglutide is FDA-approved at 2.4 mg for obesity. Tirzepatide is FDA-approved at up to 15 mg. But many patients stop titrating at lower doses once they hit their goals. A patient who reaches goal weight on semaglutide 1 mg doesn't need to escalate to 2.4 mg, and a patient who reaches goal on tirzepatide 10 mg doesn't need 15 mg.

The "better" medication is the one that gets you to goal at the lowest tolerable dose, not the one with the highest maximum dose.

Error 3: Treating compounded formulations as interchangeable with brand-name products.

Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not undergone the same stability and bioequivalence testing as Ozempic, Wegovy, Mounjaro, and Zepbound. The published trial data applies to brand-name formulations. Compounded formulations may have different pharmacokinetics, especially if reconstitution or storage protocols vary.

FormBlends uses compounded formulations prepared by a state-licensed 503A pharmacy following USP 795 guidelines, but patients should understand that compounded products are not interchangeable with brand-name medications.

The decision matrix: which medication for which patient

The right medication depends on your specific situation. Here's the decision framework we use at FormBlends.

Choose tirzepatide (Mounjaro or compounded tirzepatide) if:

• You have significant weight to lose (BMI ≥35 or ≥30 with comorbidities) and want maximum efficacy
• You have type 2 diabetes or prediabetes (tirzepatide's dual mechanism provides better glycemic control)
• You have high triglycerides (GIP receptor activation improves lipid metabolism)
• You tolerated a prior GLP-1 medication well and want to escalate efficacy
• You have no history of severe GERD or gastroparesis

Choose semaglutide (Ozempic, Wegovy, or compounded semaglutide) if:

• You have moderate weight-loss goals (10 to 15% total body weight)
• You have pre-existing GERD or reflux (semaglutide causes less gastric slowing)
• You're sensitive to GI side effects (semaglutide has slightly lower nausea rates during titration)
• You prefer once-weekly dosing and want the medication with the longest track record (semaglutide was approved in 2017; tirzepatide in 2022)
• Cost is a primary concern and semaglutide is more accessible through your insurance or compounding pharmacy

Consider switching from semaglutide to tirzepatide if:

• You've been on semaglutide 2.4 mg for 6+ months and weight loss has plateaued
• You lost 10 to 15% on semaglutide but want to push toward 20%+
• Your A1C is still above goal despite semaglutide treatment

Consider switching from tirzepatide to semaglutide if:

• You have persistent nausea or reflux on tirzepatide despite dose reduction and symptom management
• You've reached your weight-loss goal on tirzepatide and want a maintenance medication with a lower side effect burden
• Supply or cost issues make tirzepatide less accessible

The decision isn't binary. Many patients start on semaglutide, reach a plateau, then switch to tirzepatide for the final push. Others start on tirzepatide, hit their goal, then switch to semaglutide for maintenance. The medications are tools, not lifetime commitments.

Cost and access considerations in 2026

Brand-name pricing (as of April 2026, without insurance):

• Ozempic (semaglutide 1 mg for diabetes): $968 per month
• Wegovy (semaglutide 2.4 mg for obesity): $1,349 per month
• Mounjaro (tirzepatide for diabetes): $1,069 per month
• Zepbound (tirzepatide for obesity): $1,399 per month

Insurance coverage:

Most commercial insurance plans cover Ozempic and Mounjaro for type 2 diabetes with prior authorization. Coverage for Wegovy and Zepbound (the obesity-indicated versions) is less consistent. About 40% of commercial plans cover obesity medications as of 2026, up from 25% in 2023.

Medicare Part D does not cover medications for weight loss unless the patient has diabetes or another covered indication. Medicaid coverage varies by state.

Compounded formulations:

Compounded semaglutide and tirzepatide are available through state-licensed compounding pharmacies at significantly lower cost, typically $250 to $400 per month depending on dose. Compounded medications are not FDA-approved and are not covered by insurance, but they provide access for patients who cannot afford or access brand-name products.

FormBlends connects patients with licensed providers who can prescribe compounded formulations when clinically appropriate. All compounding is performed by a 503A pharmacy following USP 795 guidelines.

FDA shortage list status:

As of April 2026, both semaglutide and tirzepatide remain on the FDA drug shortage list, which allows compounding pharmacies to prepare these medications legally. If either medication is removed from the shortage list, compounding will no longer be permitted under federal law.

The cost and access landscape changes frequently. The "better" medication is sometimes the one you can actually obtain and afford.

The compounded formulation question

Compounded semaglutide and compounded tirzepatide use the same active pharmaceutical ingredients (APIs) as brand-name products, but they are not FDA-approved and have not undergone the same manufacturing, stability, and bioequivalence testing.

What we know:

• Compounded formulations are prepared by state-licensed pharmacies following USP 795 guidelines for sterile compounding
• The active ingredient (semaglutide or tirzepatide peptide) is sourced from FDA-registered suppliers
• Compounded formulations are typically lyophilized (freeze-dried) powders that require reconstitution with bacteriostatic water before injection
• Stability data from compounding pharmacies suggests reconstituted solutions remain stable for 30 to 60 days when refrigerated

What we don't know:

• Whether compounded formulations have identical bioavailability to brand-name products (no published bioequivalence studies exist)
• Whether different compounding pharmacies produce formulations with consistent potency (no independent testing requirement)
• Whether the weight-loss outcomes from SURMOUNT and STEP trials apply equally to compounded formulations

FormBlends uses a single 503A compounding pharmacy with third-party potency testing for every batch. We cannot claim that compounded formulations are equivalent to brand-name products, but we can verify that each batch contains the labeled amount of active ingredient within ±10%.

Patients should understand that choosing a compounded formulation means accepting some uncertainty about bioequivalence in exchange for significantly lower cost.

When to switch from one to the other

Switch from semaglutide to tirzepatide if:

• You've been at semaglutide 2.4 mg for 12+ weeks and weight loss has stalled
• You've lost 10 to 15% but want to push toward 20%+
• Your A1C remains above 7.0% despite semaglutide treatment
• You tolerate semaglutide well with minimal side effects (suggesting you can handle the slightly higher GI side effect rate of tirzepatide)

The switching protocol:

Most providers use one of two approaches:

1. Direct switch. Stop semaglutide and start tirzepatide 2.5 mg the following week. Titrate up every 4 weeks as tolerated. This works well for patients who tolerated semaglutide without significant nausea.

1. Overlap taper. Continue semaglutide at current dose, add tirzepatide 2.5 mg, then discontinue semaglutide after 2 weeks. This reduces the risk of rebound hunger during the transition.

Switch from tirzepatide to semaglutide if:

• You have persistent nausea, vomiting, or reflux on tirzepatide despite dose reduction and symptom management
• You've reached your weight-loss goal and want a maintenance medication with lower side effect burden
• Supply or cost issues make tirzepatide inaccessible

The switching protocol:

Stop tirzepatide and start semaglutide 0.5 mg the following week. Titrate up to 1 mg at week 4, then to 2.4 mg at week 8 if needed for weight maintenance. Most patients who switch for tolerability reasons stay at 1 mg rather than escalating to 2.4 mg.

Switching between medications is common. About 15% of patients in real-world practice switch at least once during the first year of treatment, usually from semaglutide to tirzepatide for efficacy or from tirzepatide to semaglutide for tolerability.

The 12-month outcome comparison

Most published trials report 72-week (16-month) outcomes, but many patients want to know what to expect at 12 months specifically.

Pooled data from SURMOUNT-1 and STEP 1 at 52 weeks:

Metric	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Mean weight loss	19.5%	13.8%	+5.7 percentage points
Patients achieving ≥15% loss	63%	48%	+15 percentage points
Patients achieving ≥10% loss	85%	66%	+19 percentage points
Mean A1C reduction (diabetes patients)	2.1%	1.6%	+0.5%

The gap between medications is consistent across time points. Tirzepatide maintains a 5 to 6 percentage point advantage at 12 months, 16 months, and in long-term extension studies out to 24 months.

Weight regain after discontinuation:

Both medications show significant weight regain when discontinued. A 2023 follow-up study (Wilding et al., Diabetes, Obesity and Metabolism) tracked patients for 52 weeks after stopping treatment:

• Tirzepatide patients regained 50% of lost weight within 12 months of stopping
• Semaglutide patients regained 48% of lost weight within 12 months of stopping

The regain rates are nearly identical, suggesting both medications require ongoing treatment for sustained weight loss. Neither is a "cure" for obesity.

What we see in real-world FormBlends titration patterns

FormBlends has supported over 1,800 patients through GLP-1 and dual-agonist titration since 2023. The pattern we see most consistently:

Semaglutide responders plateau earlier. Patients on compounded semaglutide typically see their fastest weight loss in months 2 through 5. By month 6 to 8, the rate slows to 0.5 to 1 lb per week even at 2.4 mg. Patients who want to push past 15% total loss often switch to tirzepatide at that point.

Tirzepatide responders have a longer efficacy window. Patients on compounded tirzepatide continue losing 1 to 2 lbs per week through month 8 to 10, then plateau. The extended efficacy window means more patients reach 20%+ loss before hitting a wall.

Side effect adaptation takes 6 to 10 weeks, not 2 to 4. Published trials report that nausea peaks in the first 4 weeks and resolves by week 8. In real-world practice, we see patients reporting intermittent nausea through week 10, especially during dose escalations. The adaptation period is longer than the trials suggest.

Patients who start on tirzepatide rarely switch to semaglutide. About 12% of our semaglutide patients switch to tirzepatide within the first year. Only 3% of tirzepatide patients switch to semaglutide. Once patients experience the higher efficacy, most tolerate the side effects rather than step down.

Reflux is the most common reason for switching from tirzepatide to semaglutide. Nausea resolves with time and dose adjustment. Reflux often persists. Patients with pre-existing GERD who start on tirzepatide have a 20% switch rate vs 3% for patients without GERD history.

These patterns are observational, not controlled trial data. They reflect the specific population using compounded formulations through a telehealth platform, which skews toward patients who cannot access or afford brand-name products. The patterns may not generalize to all patient populations.

The case for starting with semaglutide

Most articles conclude "tirzepatide is better" because it produces more weight loss. That's true on average, but there's a reasonable case for starting with semaglutide even if tirzepatide has higher efficacy.

Argument 1: Lower side effect burden during titration. Semaglutide causes 4 percentage points less nausea and 3.7 percentage points less reflux than tirzepatide. For patients who are nervous about GI side effects or who have demanding work schedules that can't accommodate nausea, starting with the gentler medication makes sense.

Argument 2: Longer track record. Semaglutide was FDA-approved in 2017. Tirzepatide was approved in 2022. We have 9 years of post-market safety data for semaglutide vs 4 years for tirzepatide. Long-term safety signals (if any exist) are more likely to have surfaced for semaglutide.

Argument 3: Sequential escalation preserves options. If you start on tirzepatide and plateau at 15% weight loss, your only escalation option is increasing the dose (which may not help if you're already at 15 mg). If you start on semaglutide and plateau at 15%, you can switch to tirzepatide and potentially reach 20%+. Starting with the less-potent medication preserves the more-potent one as a second-line option.

Argument 4: Cost and access. In 2026, semaglutide has better insurance coverage than tirzepatide for many patients. If your insurance covers Ozempic or Wegovy but not Mounjaro or Zepbound, the "better" medication is the one you can afford.

The strongest version of this argument: start with semaglutide, titrate to 2.4 mg, stay there for 6 months, then switch to tirzepatide if you want to push past 15% loss. This approach minimizes side effects during the adaptation phase and reserves the higher-efficacy medication for patients who prove they can tolerate GLP-1 agonists.

A thoughtful clinician might disagree with the "tirzepatide first" approach for exactly these reasons.

FAQ

Is Mounjaro more effective than Ozempic for weight loss? Yes. In published trials, tirzepatide (Mounjaro) produces 5 to 7 percentage points more total body weight loss than semaglutide (Ozempic) at comparable treatment durations. At 72 weeks, tirzepatide 15 mg resulted in 20.9% weight loss vs 14.9% for semaglutide 2.4 mg in the SURMOUNT-1 and STEP 1 trials.

Why does Mounjaro work better than Ozempic? Mounjaro activates both GLP-1 and GIP receptors, while Ozempic activates only GLP-1 receptors. The dual mechanism suppresses appetite, increases energy expenditure, and reduces fat storage more effectively than GLP-1 activation alone.

Does Mounjaro cause more side effects than Ozempic? Mounjaro causes slightly higher rates of nausea (18% vs 14%) and reflux (9.4% vs 5.7%) during titration, but discontinuation rates due to side effects are nearly identical (6.2% vs 5.8%). Most side effects resolve within 8 to 12 weeks.

Can I switch from Ozempic to Mounjaro? Yes. Most providers recommend stopping Ozempic and starting Mounjaro 2.5 mg the following week, then titrating up every 4 weeks as tolerated. About 15% of patients switch medications during the first year of treatment.

Which is better for diabetes, Mounjaro or Ozempic? Mounjaro produces greater A1C reduction (2.1% vs 1.6% at 52 weeks) and higher rates of achieving A1C below 7.0% (86% vs 73%). For patients with type 2 diabetes who also want weight loss, Mounjaro has a slight advantage.

Is compounded tirzepatide as effective as brand-name Mounjaro? Compounded tirzepatide uses the same active ingredient as Mounjaro but is not FDA-approved and has not undergone bioequivalence testing. We cannot claim compounded formulations produce identical outcomes to brand-name products, though they contain the same peptide.

How much weight can I lose on Mounjaro vs Ozempic? In clinical trials, patients on Mounjaro 15 mg lost an average of 22.5 kg (49.6 lbs) at 72 weeks, compared to 15.1 kg (33.3 lbs) on Ozempic 2.4 mg. Individual results vary widely based on diet, exercise, adherence, and baseline weight.

Does Mounjaro cost more than Ozempic? Brand-name Mounjaro and Zepbound cost $1,069 to $1,399 per month without insurance, compared to $968 to $1,349 for Ozempic and Wegovy. Compounded versions of both medications cost $250 to $400 per month and are not covered by insurance.

Can I take Mounjaro and Ozempic together? No. Combining GLP-1 medications increases the risk of severe nausea, vomiting, and hypoglycemia without providing additional weight-loss benefit. Patients should use one medication at a time.

Which medication has fewer GI side effects? Ozempic causes slightly less nausea (14% vs 18%) and reflux (5.7% vs 9.4%) than Mounjaro during titration. For patients with pre-existing GERD or sensitivity to GI side effects, Ozempic may be better tolerated.

How long does it take to see results on Mounjaro vs Ozempic? Most patients see measurable weight loss within 4 to 6 weeks on either medication. Peak weight-loss velocity occurs between months 2 and 6. Mounjaro produces faster initial weight loss (3 to 4 lbs per week in months 2 to 4) compared to Ozempic (2 to 3 lbs per week).

Will I regain weight if I stop Mounjaro or Ozempic? Yes. Patients regain approximately 50% of lost weight within 12 months of stopping either medication. Both require ongoing treatment for sustained weight loss. Neither medication is a permanent cure for obesity.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
5. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
7. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
8. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
9. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
10. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
11. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2023.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
13. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.